232275-73-9

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-4-AMINO-2-CHLOROBENZOIC ACID is used as a synthetic intermediate for the preparation of various bioactive molecules. Its role in the creation of new drugs and chemical entities is pivotal, given its ability to contribute to the development of innovative therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, N-BOC-4-AMINO-2-CHLOROBENZOIC ACID is utilized as a precursor in the synthesis of compounds that possess pesticidal or herbicidal properties. Its involvement in the development of these agrochemicals is essential for enhancing crop protection and yield.
Used in Organic Synthesis:
N-BOC-4-AMINO-2-CHLOROBENZOIC ACID is employed as a versatile building block in organic synthesis. Its unique reactivity and protective BOC group allow for the creation of a wide range of chemical entities, facilitating advancements in both medicinal and agricultural chemistry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 2457-76-3 4-amino-2-chlorobenzoic acid 

Downstream Products

• 232275-74-0 2-chloro-4-[N-methyl-N-(tert-butoxycarbonyl)amino]benzoic acid methyl ester 
• 937040-25-0 (2-chloro-4-methylamino-phenyl)-methanol 
• 204972-82-7 2-chloro-4-(methylamino)benzoic acid methyl ester 

Relevant academic research and scientific papers

Inhibitors of α4 mediated cell adhesion

The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur, W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R1, R2and R3are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4is tetrazolyl, carboxyl group, amide or ester; R5is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl etc.; R6is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.

Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: Discovery of TR-14035, a dual α4β7/α4β1 integrin antagonist

α4β1 and α4β7 integrins are key regulators of physiologic and pathologic responses in inflammation and autoimmune disease. The effectiveness of anti-integrin antibodies to attenuate a number of inflammatory/immune conditions provides a strong rationale to target integrins for drug development. Important advances have been made in identifying potent and selective candidates, peptides and peptidomimetics, for further development. Herein, we report the discovery of a series of novel N-benzoyl-L-biphenylalanine derivatives that are potent inhibitors of α4 integrins. The potency of the initial lead compound (1: IC50 α4β7/α4β1 =5/33 μM) was optimized via sequential manipulation of substituents to generate low nM, orally bioavailable dual α4β1/α4β7 antagonists. The SAR also led to the identification of several subnanomolar antagonists (134, 142, and 143). Compound 81 (TR-14035; IC50 α4β7/α4β1 =7/87 nM) has completed Phase I studies in Europe. The synthesis, SAR and biological evaluation of these compounds are described.